Lung deposition of a liposomal cyclosporine a inhalation solution in patients after lung transplantation

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 22, Issue 2, 2009, Pages 121-129

  Behr, Juergen ^a   Zimmermann, Gregor ^a   Baumgartner, Rainer ^a   Leuchte, Hanno ^a   Neurohr, Claus ^a   Brand, Peter ^b   Herpich, Christine ^b   Sommerer, Kurt ^c   Seitz, Jochen ^c   Menges, Gerhard ^c   Tillmanns, Sascha ^c   Keller, Manfred ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b Inamed Research GmbH and Co KG   (Germany)

^c Pari Pharma GmbH   (Germany)

Author keywords

Aerosol; Cyclospsorine A; Inhalation; Liposomes; Lung transplantation

Indexed keywords

CYCLOSPORIN;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG TOLERABILITY; FORCED EXPIRATORY VOLUME; GAMMA SCINTIGRAPHY; HUMAN; IN VITRO STUDY; INHALER; LIPOSOMAL DELIVERY; LUNG DEPOSIT; LUNG TRANSPLANTATION; NEBULIZER;

ADMINISTRATION, INHALATION; AEROSOLS; AGED; BRONCHIOLITIS OBLITERANS; CHEMISTRY, PHARMACEUTICAL; CYCLOSPORINE; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIPOSOMES; LUNG; LUNG TRANSPLANTATION; MALE; MIDDLE AGED; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M PENTETATE; VITAL CAPACITY;

EID: 67549106817     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2008.0714     Document Type: Article

References (28)

1. Trulock E, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor DO, Dobbels F, Rahmel AO, Keck BM, and Hertz MI: Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heartlung transplantation report-2007. J Heart Lung Transplant. 2007;26:782-795.
2. Hachem RR, and Trulock EP: Bronchiolitis obliterans syndrome: pathogenesis and management. Semin Thorac Cardiovasc Surg. 2004;16:350-355.
3. Knoop C, Haverich A, and Fischer S: Immunosuppressive therapy after human lung transplantation. Eur Respir J. 2004;23:159-171.
4. Trulock EP, Edwards LB, Taylor DO, Boucek MN, Mohacsi PJ, Keck BM, and Hertz MI: The registry of the International Society for Heart and Lung Transplantation: twentieth official adult lung heart-lung transplant report 2003. J Heart Lung Transplant. 2003;22:625-635.
5. Boehler A, and Estenne M: Post-transplant bronchiolitis obliterans. Eur Respir J. 2003;22:1007-1018.
6. Chan CK, Hyland RH, and Hutcheon MA: Pulmonary complications following bone marrow transplantation. Clin Chest Med. 1990;11:323-332.
7. Marras T, and Chan C: Obliterative bronchiolitis complicating bone marrow transplantation. Semin Respir Crit Care Med. 2003;24:531-541.
8. Philit F, Wiesendanger T, Archimbaud E, Mornex JF, Brune J, Cordier JF. Post transplant obstructive lung disease ("bronchiolitis obliterans"): a clinical comparative study of bone marrow and lung transplant patients. Eur Respir J. 1995;8:551-558.
9. Soubani AO, and Uberti JP: Bronchiolitis obliterans following haematopoietic stem cell transplantation. Eur Respir J. 2007;29:1007-1019.
10. Yousem SA, Berry GJ, Cagle PT, Chamberlain D, Hasain AN, Hraban RH, Marchevsky A, Ohori NP, Ritter J, Stewart S, and Tazelaar HD: Revision of the 1990 working formulation for the classification of pulmonary allograft rejection Lung Rejection Study Group. J Heart Lung Transplant. 1996;15:1-15.
11. Halloran PF, Homik J, Goes N, Lui SL, Urmson J, Ramassar V, and Cockfield SM: The "injury response": a concept linking nonspecific injury, acute rejection, and long-term transplant outcomes. Transplant Proc. 1997;29:79-81.
12. Cooper JD, Billingham M, Egan T, Egan T, Hertz MI, Higenbottam T, Lynch J, Mauer J, Paradis I, Patterson GA, Smith C, et al. A working formulation for the standardization of nomenclature for clinical staging of chronic dysfunction in lung allo-grafts: International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 1993;12:713-716.
13. Estenne M, Maurer JR, Boehler A, Egan JJ, Frost A, Hertz M, Mallory GG, Snell GI, and Yousem S: Bronchiolitis obliter-ans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant. 2002;21:297-310.
14. Trulock E, Edwards L, Taylor D, Boucek M, Keck B, Hertz M, and International Society for Heart and Lung Transplantation: Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report - 2006. J Heart Lung Transplant 2006;25:880-892.
15. Valentine VG, Robbins RC, Berry GJ, Patel HR, Reichenspumer H, Reitz BA, and Theodore J: Actuarial survival of heart-lung and bilateral sequential lung transplant recipients with obliterative bronchiolitis. J Heart Lung Transplant. 1996;15:371-383.
16. Bando K, Armitage JM, Paradis IL, Keenan RJ, Hardesty RL, Konishi H, Komatsu K, Stein KL, Shah AN, Bahnson HT and Griffith BP. Indications for and results of single, bilateral, and heart-lung transplantation for pulmonary hypertension. J Thorac Cardiovasc Surg. 1994;108:1056-1065.
17. Glanville AR, Aboyoun CL, Havryk A, Plit M, Rainer S, and Malouf MA: Severity of lymphocytic bronchiolitis predicts long-term outcome after lung transplantation. Am J Respir Crit Care Med. 2008;177:1033-1040.
18. Corcoran TE, Smaldone GC, Dauber JH, Smith DA, McCarry KR, Burckat GJ, Zeevi A, Griffith BP, and Iacono AT: Preservation of post-transplant lung function with aerosol cy-closporine. Eur Respir J. 2004;23:378-383.
19. Corcoran TE: Inhaled delivery of aerosolized cyclosporine. Adv Drug Deliv Rev. 2006;58:1119-1127.
20. Iacono AT, Corcoran TE, Griffith BP, Grgurich WF, Smith DA, Zeevi A, Smaldone GC, McCurry KR, Johnson BA, Dauber JH: Aerosol cyclosporine therapy in lung transplant recipients with bronchiolitis obliterans. Eur Respir J. 2004;23:384-390.
21. Iacono AT, Johnson BA, Grgurich WF, Youseff JG, Corcoran TE, Seiler DA, Dauber JH, Smaldone GC, Zeevi A, Yousem SA, Fung JJ, Burckart GJ, McCurry KR, and Griffith BP: A randomized trial of inhaled cyclosporine in lung-transplant recipients. N Engl J Med. 2006;354:141-150.
22. Gilbert BE, Knight C, Alvarez FG, Wadrep C, Rodarte JR, Knight V, Eschenbacher WL: Tolerance of volunteers to cy-closporine A- dilauroylphosphatidylcholine liposome aerosol. Am J Respir Crit Care Med. 1997;156:1789-1793.
23. Behr J, Menges G, Keller M, Bitterle E, Baumgartner R, Zimmermann G, Herpich C, Sommerer K, and Seitz J: Lung deposition of a liposomal cyclosporine A inhalation solution in patients after lung transplantation. Proc Drug Del Lungs. 2006;17:22-25.
24. Akkar A, Bitterle E, Gruber F, and Keller M: Characterization of a liposomal Cyclosporine A formulation for nebulization into the lungs of transplanted patients and useful for other topical administrations. Poster No. AM-07-01563 presented at the annual conference of the American Association of Pharmaceutical Scientists (AAPS) in San Diego Nov. 11-15, 2007.
25. Knoch M, and Keller M: The customized electronic nebuliser eFlow®. A new category of liquid aerosol drug delivery system. Expert Opin Drug Deliv. 2005;2:377-390.
26. Keller M, Bitterle E, Tservistas M, Steinfuehrer K, Aslihan A, Mueller J, Bock U, and Haltner E: Cyclosporine A: investigation on formulation dependent toxicity in a calu-3 cell culture model and characterization of aerosols generated by the eFlow® electronic nebulizer. Proc Respir Drug Del. 2006;729-732.
27. Pitcairn GR, and Newman SP: Tissue attenuation corrections in gammascintigraphy. J Aerosol Med. 1997;10:187-198.
28. Agnew JE: Characterizing lung aerosol penetration. J Aerosol Med. 1991;4:237-249.